- Home
- FPF vs ELVN Comparison
FPF vs ELVN Comparison
Compare FPF & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPF
- ELVN
- Stock Information
- Founded
- FPF 2013
- ELVN 2016
- Country
- FPF United States
- ELVN United States
- Employees
- FPF N/A
- ELVN N/A
- Industry
- FPF Trusts Except Educational Religious and Charitable
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- FPF Finance
- ELVN Health Care
- Exchange
- FPF Nasdaq
- ELVN Nasdaq
- Market Cap
- FPF 1.1B
- ELVN 927.8M
- IPO Year
- FPF N/A
- ELVN 2020
- Fundamental
- Price
- FPF $18.83
- ELVN $20.64
- Analyst Decision
- FPF
- ELVN Strong Buy
- Analyst Count
- FPF 0
- ELVN 5
- Target Price
- FPF N/A
- ELVN $41.20
- AVG Volume (30 Days)
- FPF 186.7K
- ELVN 750.0K
- Earning Date
- FPF 01-01-0001
- ELVN 08-12-2025
- Dividend Yield
- FPF 8.08%
- ELVN N/A
- EPS Growth
- FPF N/A
- ELVN N/A
- EPS
- FPF N/A
- ELVN N/A
- Revenue
- FPF N/A
- ELVN N/A
- Revenue This Year
- FPF N/A
- ELVN N/A
- Revenue Next Year
- FPF N/A
- ELVN N/A
- P/E Ratio
- FPF N/A
- ELVN N/A
- Revenue Growth
- FPF N/A
- ELVN N/A
- 52 Week Low
- FPF $13.91
- ELVN $13.30
- 52 Week High
- FPF $18.09
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- FPF 72.55
- ELVN 51.64
- Support Level
- FPF $18.60
- ELVN $19.22
- Resistance Level
- FPF $18.87
- ELVN $21.90
- Average True Range (ATR)
- FPF 0.14
- ELVN 1.49
- MACD
- FPF 0.03
- ELVN -0.22
- Stochastic Oscillator
- FPF 93.28
- ELVN 37.81
About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.